Current Report Filing (8-k)
September 21 2016 - 9:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 20, 2016
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-37348
|
|
46-4348039
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
100
River Ridge Drive, Norwood, MA
|
|
02062
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(617) 963-0100
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
1.01. Entry into a Material Definitive Agreement.
On
September 20, 2016, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) entered into a consulting agreement (the
“Consulting Agreement”) with Orchestra Medical Ventures, LLC, a Delaware limited liability company (“Orchestra”),
a healthcare investment management firm, pursuant to which Orchestra will provide consulting and advisory services related to
identifying and evaluating strategic relationships, licensing opportunities and business strategies for the Company. David Hochman,
a member of the Company’s Board of Directors, is the Managing Partner of Orchestra.
The
term of the Consulting Agreement will commence on September 20, 2016 and expire on March 20, 2017, subject to renewal upon mutual
agreement of the parties. Pursuant to the terms of the Consulting Agreement, the Company will pay to Orchestra cash compensation
in an aggregate amount of $100,000, payable in equal monthly installments. In addition, as approved by the Company’s Compensation
Committee, effective as of September 16, 2016, the Company granted an equity incentive award to Orchestra consisting of options
to purchase 50,000 shares (the “Option Shares”) of the Company’s common stock, par value $0.0001 per share,
(the “Option Award”) pursuant to the Company’s 2014 Equity Compensation Plan (the “Plan”). The Option
Award shall be made in accordance with the terms of the Plan and fifty percent (50%) of the Option Shares will vest on the three
(3) month anniversary of the date of grant of the Option Award with the remainder of the Option Shares vesting on the six (6)
month anniversary of the date of grant of the Option Award.
The
foregoing summary of the Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to
the Consulting Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report.
Item
9.01. Financial Statements and Exhibits.
Exhibit
No.
|
|
Description
|
|
|
|
10.1
|
|
Consulting
Agreement, dated September 20, 2016, by and between the Company and Orchestra
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORBUS
PHARMACEUTICALS HOLDINGS, INC.
|
|
|
|
Dated:
September 21, 2016
|
By:
|
/s/
Yuval Cohen
|
|
Name:
|
Yuval
Cohen
|
|
Title:
|
Chief Executive Officer
|
Exhibit
Index
Exhibit
No.
|
|
Description
|
|
|
|
10.1
|
|
Consulting
Agreement, dated September 20, 2016, by and between the Company and Orchestra
|
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024